Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial

Nina Kimer, Henning Grønbæk, Rikard Gøran Fred, Torben Hansen, Atul Shahaji Deshmukh, Mathias Mann, Flemming Bendtsen, Nina Kimer, Henning Grønbæk, Rikard Gøran Fred, Torben Hansen, Atul Shahaji Deshmukh, Mathias Mann, Flemming Bendtsen

Abstract

Introduction: Patients with liver cirrhosis are often diagnosed late and once complications are present, the 2-year survival is 50%. Increasing evidence supports systemic inflammation and metabolic dysfunction in the hepatic stellate cell as key drivers of progression of cirrhosis. However, there is no registered medication, that targets inflammation and cellular dysfunction in the liver.

Methods and analysis: In a randomised double-blind and placebo-controlled trial with atorvastatin for liver cirrhosis, we aim to investigate clinical endpoints of survival, hospitalisations and safety, but also exploratory endpoints of genomics and protein functions in the liver.

Ethics and dissemination: There is no registered medication that actively prevents development of complications or systemic inflammation in liver cirrhosis. All patients continue regular clinical management during the trial period. Atorvastatin has been on the market for several years with a safety profile that is acceptable even in patients with liver disease. A beneficial effect of atorvastatin on clinical outcomes in cirrhosis will provide cheap and effective causal treatment for chronic liver disease. The trial is registered by the Danish Data Protection Agency (P-2019-635) and approved by the Danish Medicines Agency (EudraCT 2019-001806-40) and the Scientific Ethics Committee of the Capital Region of Denmark (H-19030643) before initiation. Reporting of the trial will follow the Consolidated Standards of Reporting Trials guidelines for reporting of randomised clinical trials.

Trial registration number: The trial is registered in clinicaltrials.gov (NCT04072601) and in clinicaltrialsregister.eu (EudraCT 2019-001806-40) (Pre-results).

Keywords: clinical pharmacology; clinical trials; hepatobiliary disease; hepatology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Trial flow.
Figure 2
Figure 2
Graphical abstract.

References

    1. Jepsen P, Vilstrup H, Sørensen HT. Alcoholic cirrhosis in Denmark - population-based incidence, prevalence, and hospitalization rates between 1988 and 2005: a descriptive cohort study. BMC Gastroenterol 2008;8:3 10.1186/1471-230X-8-3
    1. Berman K, Tandra S, Forssell K, et al. . Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. Clin Gastroenterol Hepatol 2011;9:254–9. 10.1016/j.cgh.2010.10.035
    1. Jepsen P, Ott P, Andersen PK, et al. . Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology 2010;51:1675–82. 10.1002/hep.23500
    1. Clària J, Stauber RE, Coenraad MJ, et al. . Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 2016;64:1249–64. 10.1002/hep.28740
    1. Abraldes JG, Albillos A, Bañares R, et al. . Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009;136:1651–8. 10.1053/j.gastro.2009.01.043
    1. Dhar A, Tschotazis E, Brown R, et al. . LP11 : Warfarin anticoagulation for liver fibrosis in patients transplanted for hepatitis C (WAFT-C): results at one year. J Hepatol 2015;62:S268–9. 10.1016/S0168-8278(15)30165-3
    1. Kimer N, Pedersen JS, Busk TM, et al. . Rifaximin has no effect on hemodynamics in decompensated cirrhosis: a randomized, double-blind, placebo-controlled trial. Hepatology 2017;65:592–603. 10.1002/hep.28898
    1. Krenkel O, Hundertmark J, Ritz TP, et al. . Single cell RNA sequencing identifies subsets of hepatic stellate cells and myofibroblasts in liver fibrosis. Cells 2019;8:503 10.3390/cells8050503
    1. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 2017;14:397–411. 10.1038/nrgastro.2017.38
    1. Kamal S, Khan MA, Seth A, et al. . Beneficial effects of statins on the rates of hepatic fibrosis, hepatic decompensation, and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastroenterol 2017;112:1495–505. 10.1038/ajg.2017.170
    1. Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment Pharmacol Ther 2017:APT0908-2017.R1 10.1111/apt.14243
    1. Abraldes JG, Villanueva C, Aracil C, et al. . Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 2016;150:e1163:1160–70. 10.1053/j.gastro.2016.01.004
    1. Yebyo HG, Aschmann HE, Kaufmann M, et al. . Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am Heart J 2019;210:18–28. 10.1016/j.ahj.2018.12.007
    1. Zhang W, Zhang Y, Li C-W, et al. . Effect of statins on COPD: a meta-analysis of randomized controlled trials. Chest 2017;152:1159–68. 10.1016/j.chest.2017.08.015
    1. Kalinowski L, Dobrucki LW, Brovkovych V, et al. . Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 2002;105:933–8. 10.1161/hc0802.104283
    1. Lefer DJ. Statins as potent antiinflammatory drugs. Circulation 2002;106:2041–2. 10.1161/01.CIR.0000033635.42612.88
    1. McGirt MJ, Lynch JR, Parra A, et al. . Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002;33:2950–6. 10.1161/01.STR.0000038986.68044.39
    1. Gupta TK, Toruner M, Chung MK, et al. . Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926–31. 10.1002/hep.510280405
    1. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344–51. 10.1016/S0016-5085(98)70487-1
    1. Abraldes JG, Rodríguez-Vilarrupla A, Graupera M, et al. . Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 2007;46:1040–6. 10.1016/j.jhep.2007.01.020
    1. Trebicka J, Hennenberg M, Laleman W, et al. . Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 2007;46:242–53. 10.1002/hep.21673
    1. Chong L-W, Hsu Y-C, Lee T-F, et al. . Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol 2015;15:22 10.1186/s12876-015-0248-8
    1. Zafra C, Abraldes JG, Turnes J, et al. . Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749–55. 10.1053/j.gastro.2003.12.007
    1. Cash WJ, O'Neill S, O'Donnell ME, et al. . Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013;33:1166–74. 10.1111/liv.12191
    1. Pollo-Flores P, Soldan M, Santos UC, et al. . Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig Liver Dis 2015;47:957–63. 10.1016/j.dld.2015.07.156
    1. Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment Pharmacol Ther 2017;46:673–80. 10.1111/apt.14243
    1. Rodríguez S, Raurell I, Torres-Arauz M, et al. . A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci Rep 2017;7:40461 10.1038/srep40461
    1. Bishnu S, Ahammed SM, Sarkar A, et al. . Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study. Eur J Gastroenterol Hepatol 2018;30:54–9. 10.1097/MEG.0000000000001006
    1. Simon TG, Bonilla H, Yan P, et al. . Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 2016;64:47–57. 10.1002/hep.28506
    1. Pose E, Trebicka J, Mookerjee RP, et al. . Statins: old drugs as new therapy for liver diseases? J Hepatol 2019;70:194–202. 10.1016/j.jhep.2018.07.019
    1. Geyer PE, Kulak NA, Pichler G, et al. . Plasma proteome profiling to assess human health and disease. Cell Syst 2016;2:185–95. 10.1016/j.cels.2016.02.015
    1. Geyer PE, Wewer Albrechtsen NJ, Tyanova S, et al. . Proteomics reveals the effects of sustained weight loss on the human plasma proteome. Mol Syst Biol 2016;12:901 10.15252/msb.20167357
    1. Kulak NA, Geyer PE, Mann M. Loss-less Nano-fractionator for high sensitivity, high coverage proteomics. Mol Cell Proteomics 2017;16:694–705. 10.1074/mcp.O116.065136
    1. Kulak NA, Pichler G, Paron I, et al. . Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat Methods 2014;11:319–24. 10.1038/nmeth.2834
    1. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008;26:1367–72. 10.1038/nbt.1511
    1. Tyanova S, Temu T, Sinitcyn P, et al. . The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 2016;13:731–40. 10.1038/nmeth.3901
    1. Di Costanzo A, Belardinilli F, Bailetti D, et al. . Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy. Sci Rep 2018;8:3702 10.1038/s41598-018-21939-0
    1. Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016;65:1026–37. 10.1016/j.metabol.2015.08.018
    1. Wagner A, Regev A, Yosef N. Revealing the vectors of cellular identity with single-cell genomics. Nat Biotechnol 2016;34:1145–60. 10.1038/nbt.3711
    1. Snyder MW, Kircher M, Hill AJ, et al. . Cell-free DNA comprises an in vivo nucleosome footprint that informs its Tissues-Of-Origin. Cell 2016;164:57–68. 10.1016/j.cell.2015.11.050
    1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver . EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018;69:406–60. 10.1016/j.jhep.2018.03.024
    1. Tandon P, Tangri N, Thomas L, et al. . A rapid bedside screen to predict unplanned hospitalization and death in outpatients with cirrhosis: a prospective evaluation of the clinical frailty scale. Am J Gastroenterol 2016;111:1759–67. 10.1038/ajg.2016.303
    1. Kammerlind A-SC, Fristedt S, Ernsth Bravell M, et al. . Test–retest reliability of the Swedish version of the Life-Space assessment questionnaire among community-dwelling older adults. Clin Rehabil 2014;28:817–23. 10.1177/0269215514522134
    1. Rasmussen ST, Andersen JT, Nielsen TK, et al. . Simvastatin and oxidative stress in humans: a randomized, double-blinded, placebo-controlled clinical trial. Redox Biol 2016;9:32–8. 10.1016/j.redox.2016.05.007
    1. Sue MJ, Lee EW, Saab S, et al. . Transjugular liver biopsy: safe even in patients with severe coagulopathies and multiple biopsies. Clin Transl Gastroenterol 2019;10:e00063 10.14309/ctg.0000000000000063
    1. Riaz H, Khan AR, Khan MS, et al. . Meta-Analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol 2017;120:774–81. 10.1016/j.amjcard.2017.05.046
    1. Singh S, Singh PP, Singh AG, et al. . Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013;144:323–32. 10.1053/j.gastro.2012.10.005
    1. Zheng Y-X, Zhou P-C, Zhou R-R, et al. . The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2017;29:759–66. 10.1097/MEG.0000000000000867
    1. International Committee of Medical Journal Editors Uniform requirements for manuscripts submitted to biomedical journals. JAMA 1997;277:927–34. 10.1001/jama.1997.03540350077040
    1. Kaplan DE, Serper MA, Mehta R, et al. . Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology 2019;156:1693–706. 10.1053/j.gastro.2019.01.026

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir